Clinical trials: Dementia Moderate, active
Alzheimer Disease (AD)
Alzheimer's Disease Treated With Vagus Nerve Stimulation
The goal of this clinical trial is to evaluate the safety and efficacy of vagus nerve stimulation (VNS) for treating Alzheimer's disease (AD) in patients aged 50-80 years with mild cognitive impairment to moderate Alzheimer's…
- Trial name
- Advant (NCT06923007)
- Testing
- Vagus Nerve Stimulation
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 2 (NCT06976203)
- Testing
- KarXT, KarX-EC
- Where
- 128 sites in United States, Argentina and 15 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Disease
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the leading cause of dementia, affecting millions worldwide. With its global prevalence steadily increasing, particularly in low- and middle-income countries, the demand for effective treatments has…
- Trial name
- NCT06840054
- Testing
- Sodium Pentaborate Pentahydrate
- Volunteers
- 30 people
- Sponsor
- Tabriz University of Medical Sciences
Alzheimer's Disease
A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects
This study is a Phase 2b/3 clinical trial of a new candidate drug (T3D-959) to treat patients with mild-to-moderate Alzheimer's.
- Trial name
- NCT06964230
- Testing
- T3D-959
- Where
- United States
- Volunteers
- 376 people
- Sponsor
- T3D Therapeutics, Inc.
Alzheimer Disease
Implantable Vagus Nerve Stimulation Modulation of Coeruleus-Norepinephrine Network for Mild-Moderate AD Patients
A randomized controlled clinical study will be conducted in Xuanwu Hospital of Capital Medical University. This study initially explore the effect of selective vagus nerve(C fiber) stimulation on mild-to-moderate AD patients, in…
- Trial name
- NCT05575271
- Testing
- Vagus Nerve Stimulation Modulation of the Coeruleus-Norepinephrine Network
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Xuanwu Hospital, Beijing
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
Alzheimer Disease
Transcranial Near-infrared Light Therapy for Mild-Moderate Alzheimer's Disease (NIR4AD)
The goal of this study is to explore the efficacy and safety of Near-infrared light Photobiomodulation in patients with mild-moderate Alzheimer's disease(AD).
- Trial name
- NCT06160908
- Testing
- NirsCure
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer Disease
Open-Label Extension Protocol to SNK01-AD01 Study
Open-Label Extension Protocol to SNK01-AD01 Study
- Trial name
- NCT07228078
- Testing
- SNK01
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NKGen Biotech, Inc.
Alzheimer Disease, Insomnia Disorder
Daridorexant to Treat Insomnia in Patients With Mild Cognitive Impairment and Mild to Moderate Alzheimer Disease
DARIDOR-ALZ is a phase IV clinical trial designed to evaluate both the efficacy and safety of daridorexant, a selective dual orexin receptor antagonist that blocks the actions of the orexin neuropeptides at both orexin-1 and…
- Conditions
- Alzheimer Disease, Insomnia Disorder, Sleep
- Trial name
- DARIDOR-ALZ (NCT05924425)
- Testing
- Daridorexant 50 mg, Polysomnography, Neuropsychological assessment
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Montpellier
Alzheimer Disease
An Exploratory Study of Near-infrared Light Therapy for Mild to Moderate Alzheimer's Disease
This is an exploratory clinical study to evaluate the efficacy and safety of near-infrared light therapeutics in the treatment of mild to moderate Alzheimer's disease.
- Trial name
- NCT06836180
- Testing
- Near infrared light therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xuanwu Hospital, Beijing
Alzheimer Disease
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
An open label pilot study in mild to moderate AD patients to assess the effects of treatment with ECHS AD pulsed electromagnetic treatment device on disease progression. Enrolled patients will receive active devices.
- Trial name
- NCT05295615
- Testing
- ECHS AD Device
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Herrick Medical LLC
Alzheimer Disease
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
ALZN002-01 is a first-in-human, randomized, double-blind, placebo-controlled, parallel-group, phase 1/2a study of autologous amyloid beta mutant peptide-pulsed dendritic cells (ALZN002) in subjects with mild-to-moderate dementia…
- Trial name
- NCT05834296
- Testing
- ALZN002 (autologous DCs pulsed with E22W mutant peptide).
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alzamend Neuro, Inc.
Older Adults at High Risk for MCI, Older Adults With Mild to Moderate Level of Dementia
STRONGER 60+: Assessing the Clinical Effectiveness and Delivery of an Adapted FINGER Model for Brain Health in Primary Care
Background: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) was the first to show that multidomain lifestyle interventions can enhance brain health and reduce cognitive decline.
- Trial name
- STRONGER (NCT07117916)
- Testing
- Supervised nutritional guidance, physical exercise, cognitive training, social engagement, and management of vascular and metabolic risk factors., Self-Guided
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Alzheimer Disease
Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)
This phase 2 study will evaluate the safety, tolerability, clinical efficacy, pharmacokinetics, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate AD.
- Trial name
- NCT06427668
- Testing
- SPG302
- Where
- 2 sites in Australia
- Volunteers
- 24 people
- Sponsor
- Spinogenix
Alzheimer Disease, Cognitive Impairment
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)
This is an open-label extension for a multicenter, randomized, double-blind, sham-controlled, adaptive design pivotal study. Participants who complete the Hope Study (CA-0011) will be eligible to consent for screening to enroll…
- Conditions
- Alzheimer Disease, Cognitive Impairment, Mild Cognitive Impairment, Dementia, Mild
- Trial name
- NCT06245031
- Testing
- Sensory Stimulation System (GS120) - Active
- Where
- 53 sites in United States
- Volunteers
- 402 people
- Sponsor
- Cognito Therapeutics, Inc.
Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease
Large-coil Parietal Repetitive Transcranial Magnetic Stimulation (rTMS) for Alzheimer Disease (AD)
The goal of this clinical trial is to learn if using large-coil (or "deep") repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus and surrounding areas is feasible, tolerable, and potentially efficacious for…
- Conditions
- Alzheimer&Amp;Amp;#39;s Disease, Alzheimer Disease, Dementia Alzheimer Type, Mild Alzheimer&Amp;Amp;#39;s Disease
- Trial name
- PROMIS-AD (NCT06597942)
- Testing
- TMS
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, Los Angeles
Alzheimers Disease
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to…
- Trial name
- NCT04639050
- Testing
- RO7126209
- Where
- 37 sites in United States, Australia and 7 more
- Volunteers
- 241 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Alzheimer Dementia
Clinical Study to Evaluate the Efficacy and Safety of Huperzine A Controlled-Release Tablets in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type
This study is a multicenter, randomized, double-blind, double-dummy, active- and placebo-controlled, parallel-group clinical trial.
- Trial name
- NCT07066826
- Testing
- Huperzine A Controlled-Release Tablets, Donepezil hydrochloride tablets
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Wanbangde Pharmaceutical Group Co., LTD